Send to

Choose Destination
See comment in PubMed Commons below
Gastroenterology. 2011 May;140(6):1838-46. doi: 10.1053/j.gastro.2011.02.014.

Future therapeutic approaches for inflammatory bowel diseases.

Author information

Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.


In this review, we speculate about future therapeutic approaches for inflammatory bowel diseases (IBDs), focusing on the need for better preclinical and clinical models and approaches beyond small molecules and systemically administered biologics. We offer ideas to change clinical trial programs and to use immunologic and genetic biomarkers to personalize medicine. We attempt to reconcile past therapeutic successes and failures to improve future approaches. Some of our ideas might be provocative, but we hope that the examples we provide will stimulate discussion about what will advance the field of IBD therapy.

[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

The authors disclose the following: Scott E. Plevy: speaker at CME Symposia partially or completely funded: Abbott Immunology; Centocor, Inc; UCB. Advisory committees: Abbott Immunology, Centocor, Inc; Elan Pharmaceuticals; Eli Lilly; Genentech, Inc; GlaxoSmithKline; Merck; Novartis; Prometheus Laboratories; Takeda Pharmaceuticals; UCB. Stephan R. Targan: cofounder and share holder: Prometheus Laboratories.

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center